A detailed history of Perceptive Advisors LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Perceptive Advisors LLC holds 1,714,806 shares of AKRO stock, worth $52.5 Million. This represents 1.29% of its overall portfolio holdings.

Number of Shares
1,714,806
Previous 1,499,897 14.33%
Holding current value
$52.5 Million
Previous $35.2 Million 39.82%
% of portfolio
1.29%
Previous 1.02%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$21.45 - $29.34 $4.61 Million - $6.31 Million
214,909 Added 14.33%
1,714,806 $49.2 Million
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $2.06 Million - $2.77 Million
112,426 Added 8.1%
1,499,897 $35.2 Million
Q1 2024

May 15, 2024

BUY
$17.76 - $31.18 $7.45 Million - $13.1 Million
419,696 Added 43.37%
1,387,471 $35 Million
Q4 2023

Feb 14, 2024

SELL
$11.38 - $50.33 $7.42 Million - $32.8 Million
-651,650 Reduced 40.24%
967,775 $22.6 Million
Q3 2023

Nov 14, 2023

SELL
$41.19 - $52.25 $13.2 Million - $16.8 Million
-321,250 Reduced 16.55%
1,619,425 $81.9 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $52.3 Million - $80.6 Million
1,417,150 Added 270.69%
1,940,675 $90.6 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $50.24 $6.45 Million - $8.69 Million
173,000 Added 49.35%
523,525 $20 Million
Q4 2022

Feb 14, 2023

SELL
$33.44 - $54.8 $2.66 Million - $4.36 Million
-79,475 Reduced 18.48%
350,525 $19.2 Million
Q3 2022

Nov 14, 2022

BUY
$10.15 - $34.05 $4.36 Million - $14.6 Million
430,000 New
430,000 $14.6 Million
Q4 2020

Feb 16, 2021

SELL
$25.12 - $29.89 $551,082 - $655,726
-21,938 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$30.79 - $39.92 $675,471 - $875,764
21,938 New
21,938 $675,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.42B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.